Market revenue in 2023 | USD 105.5 million |
Market revenue in 2030 | USD 228.0 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.74% in 2023. Horizon Databook has segmented the Canada hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
Canada's hereditary angioedema therapeutics market is expected to witness lucrative growth. The growing prevalence and diagnosis of the condition, with an increase in investment by key players in R&D and the introduction of novel treatments to new markets is fueling the growth of overall market in the country.
However, with the rising efforts of the Canadian Hereditary Angioedema Society (CHAES) and then the Canadian Hereditary Angioedema Network (CHAEN), HAE management in Canada has improved over the last decade.
Clinical research in diagnosis, therapy, and management is ongoing in Canadian HAE clinics, and more clinics are expected to join CHAEN and participate in such clinical research. Comprehensive Care Clinics for HAE are slowly emerging, and the trend is to evolve and collaborate with the National Rare Blood Disorders Organization (NRBDO) and the NRBDO clinics that are emerging there.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Canada hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account